Cabo Verde vs Guinea-Bissau: Statin use vs. average non-HDL cholesterol levels
Cabo Verde
2.8
in 2018
Guinea-Bissau
2.8
in 2018
Cabo Verde rank
163rd
Guinea-Bissau rank
163rd
Statin use vs. average non-HDL cholesterol levels over time
- Cabo Verde
- Guinea-Bissau
How they compare
Cabo Verde currently reports 2.8 against 2.8 in Guinea-Bissau, a difference of 0.
The two have swapped places 9 times across 39 shared years of data; in 1980 it was Cabo Verde ahead.
Cabo Verde ranks 163rd and Guinea-Bissau ranks 163rd of 191 countries.
Cabo Verde has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Cabo Verde | Guinea-Bissau | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.46 | 2.41 | 0.05 | Cabo Verde |
| 1990s | 2.67 | 2.59 | 0.08 | Cabo Verde |
| 2000s | 2.76 | 2.7 | 0.06 | Cabo Verde |
| 2010s | 2.8 | 2.8 | 0 | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Cabo Verde or Guinea-Bissau?
- Cabo Verde, at 2.8 against 2.8 in Guinea-Bissau as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Cabo Verde and Guinea-Bissau?
- 0, with Cabo Verde ahead.
- How many years of comparable data are there for Cabo Verde and Guinea-Bissau?
- 39 years are reported by both, from 1980 to 2018.
- How do Cabo Verde and Guinea-Bissau rank globally for statin use vs. average non-hdl cholesterol levels?
- Cabo Verde ranks 163rd and Guinea-Bissau ranks 163rd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.